allox-scientists-map-the-first-step-in-alzheimers-protein-aggregation-and-discover-clues-for-future-therapies

In research published in Science Advances, ALLOX scientists Mireia Seuma, André Faure and Ben Lehner used large-scale genomics and machine learning to study over 140,000 versions of a peptide called Aβ42, which forms harmful plaques in the brain and is known to play a central role in Alzheimer’s disease.

ALLOX scientists map the first step in Alzheimer’s protein aggregation and discover clues for future therapies

team-update-and-celebration

We gathered together for a traditional Catalan calçotada to celebrate new teammates and new labs. With Youssef and Lukas on board, we are now 11 members in the ALLOX team, marking a significant milestone in our growth.

Team Update and Celebration

secret-vulnerabilities-of-cancers-death-star-revealed

 Researchers at the Centre for Genomic Regulation and the Wellcome Sanger Institute have validated ALLOX's foundational technology by producing the first ever complete map of allosteric sites for any complete protein: KRAS, one of the most famous and frequently mutated genes in cancer of many types.

Secret Vulnerabilities of Cancer’s ‘Death Star’ Revealed

team-update-andrei-papkou-and-grzegorz-chojnowski-join-allox

With Greg and Andrei on board, we are taking our computational platform to the next level. We recently headed out for a day of sailing and a meal together to celebrate the growing team.

Team Update: Andrei Papkou and Grzegorz Chojnowski join ALLOX

allox-launches-with-the-support-of-asabys

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the successful closing of an undisclosed pre-seed financing from Asabys’ new fund Sabadell Asabys II.

ALLOX launches with the support of Asabys

from-bottleneck-to-benchmark-how-were-scaling-bioinformatics-at-allox-using-the-seqera-platform-nextflow

As a computational team at ALLOX, we already had our ways of organizing pipelines and sharing data. We wondered: Do we really need another layer?  Six months later, the answer is a resounding yes. We explain the three aspects that turned out to be game-changers.

From Bottleneck to Benchmark: How we’re scaling Bioinformatics at ALLOX using the Seqera Platform (Nextflow)

julia-domingo-ceo-of-allox-interviewed-by-ellipse-magazine

Júlia explains how the company was born at the CRG, how the technology they developed works, and what its future holds.

Júlia Domingo, CEO of ALLOX, interviewed by El·lipse magazine

the-surprisingly-simple-genetic-architecture-of-protein-stability

In research published in Nature, André Faure and Professor Ben Lehner – co-founders of ALLOX – have discovered that the impact of mutations on protein stability is more predictable than previously thought.

The surprisingly simple genetic architecture of protein stability

allox-to-present-at-embo-embl-ai-and-biology-symposium

André Faure, ALLOX Co-founder and CDO, will present at the EMBO | EMBL AI and biology Symposium, on Wednesday, March 13th at 14:15.

ALLOX to present at EMBO | EMBL AI and biology Symposium

team-update-emilio-erazofischer-and-mireia-seuma-join-allox

Emilio, as Chief Business Officer, will identify and pursue strategic partnerships and deals to advance the company's pipeline and technology. Miriea joins as Senior Scientist to scale up the discovery of allosteric sites.

Team Update: Emilio Erazo-Fischer and Mireia Seuma join ALLOX

allox-the-startup-using-allostery-to-revolutionize-drug-development

The techbio company has just set up at the Barcelona Science Park and is emerging as one of the most promising startups in the Catalan biotechnology ecosystem.

News

Date

Category

All our switches